Comparative Effectiveness Study of Spironolactone Versus Doxycycline for Acne
Launched by UNIVERSITY OF PENNSYLVANIA · Oct 7, 2020
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effectiveness of two different treatments for acne in women: spironolactone and doxycycline. Acne is a common skin condition that can cause inflammation and discomfort, especially for adolescents and young adults. This trial aims to find out which of these two medications works better for treating moderate to severe acne, helping to reduce the need for long-term antibiotic use.
To participate in this study, women aged 16 to 40 who have a specific type of acne (at least 10 inflamed spots) may be eligible, provided they are not pregnant or planning to become pregnant. Participants will be closely monitored and will receive one of the two treatments. This trial is currently looking for volunteers, so if you or someone you know fits the criteria and is interested in helping advance acne treatment, this could be a great opportunity.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Female sex assigned at birth
- • Age 16-40 years old
- • Acne defined as at least 10 inflammatory papules or pustules and an Investigator's Global Assessment (IGA) score of at least 2 as measured by the Comprehensive Acne Severity Scale
- • Not currently pregnant or planning to become pregnant
- Exclusion Criteria:
- • Pregnancy
- • Heart disease
- • Renal disease
- • Liver disease
- • Orthostatic hypotension
- • Addison's disease
- • History of hyperkalemia
- • Allergy to tetracycline-class antibiotic
- • Allergy to spironolactone
- • Concomitant use of medications known to interact with spironolactone or doxycycline or that may increase the risk for hyperkalemia, including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, eplerenone, nonsteroidal anti-inflammatory drugs, and digoxin.
- • Treatment with spironolactone, an oral antibiotic, laser, photodynamic therapy, or chemical peel within the past 4 weeks
- • Treatment with isotretinoin within the past 3 months
- • Sebacia laser treatment within the past 12 months
About University Of Pennsylvania
The University of Pennsylvania, a prestigious Ivy League institution located in Philadelphia, is renowned for its commitment to advancing medical research and improving healthcare outcomes. As a clinical trial sponsor, the university leverages its extensive resources, interdisciplinary expertise, and cutting-edge facilities to conduct innovative studies across various therapeutic areas. With a focus on translating scientific discoveries into clinical applications, the University of Pennsylvania fosters collaborations among leading researchers, clinicians, and industry partners, ensuring rigorous trial design and adherence to ethical standards. Through its dedication to excellence in research and education, the university plays a pivotal role in shaping the future of medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Philadelphia, Pennsylvania, United States
San Francisco, California, United States
Miami, Florida, United States
Portland, Oregon, United States
New York, New York, United States
Fort Smith, Arkansas, United States
Arlington, Texas, United States
Gresham, Oregon, United States
Miami, Florida, United States
Frisco, Texas, United States
Hershey, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Indianapolis, Indiana, United States
Columbus, Ohio, United States
Cincinnati, Ohio, United States
Sherman Oaks, California, United States
N. New Hyde Park, New York, United States
Houston, Texas, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials